<?xml version="1.0"?>
<rss version="2.0">
 <channel>
  <title>StreetInsider.com News Articles</title>
  <link>http://www.streetinsider.com</link>
  <description>Latest StreetInsider.com News Articles</description>
  <language>en-us</language>
  <copyright>Copyright 2026, StreetInsider.com</copyright>
  <managingEditor>rss@streetinsider.com (SI RSS)</managingEditor>
  <webMaster>rss@streetinsider.com (SI RSS)</webMaster>
  <lastBuildDate>Tue, 20 Oct 2026 16:05:00 -0400</lastBuildDate>
  <docs>http://blogs.law.harvard.edu/tech/rss</docs>
  <image>
   <url>http://www.streetinsider.com/images/rss_logo.gif</url>
   <title>StreetInsider.com News Articles</title>
   <link>http://www.streetinsider.com</link>
   <width>143</width>
   <height>28</height>
  </image>
  <skipHours>
   <hour>0</hour>
   <hour>1</hour>
   <hour>2</hour>
   <hour>3</hour>
   <hour>21</hour>
   <hour>22</hour>
   <hour>23</hour>
  </skipHours>
  <skipDays>
   <day>Saturday</day>
   <day>Sunday</day>
  </skipDays>
  <item>
   <title>LifeMD to Report Third Quarter 2026 Financial Results on November 9</title>
   <link>http://www.streetinsider.com/Press+Releases/LifeMD+to+Report+Third+Quarter+2026+Financial+Results+on+November+9/27210422.html</link>
   <description>
&lt;p align=&quot;justify&quot;&gt;NEW YORK, Oct.  20, 2026  (GLOBE NEWSWIRE) -- &lt;strong&gt;LifeMD, Inc. (Nasdaq: LFMD)&lt;/strong&gt;, a leading provider of virtual primary care and pharmacy services, announces that it will report financial results for the three and nine months ended September 30, 2026, before the open of the U.S. financial markets on November 9, 2026, and will host a conference call beginning at 8:30 a.m. Eastern time.&lt;/p&gt;  &lt;p&gt;&lt;strong&gt;Conference Call &amp;amp; Webcast Details&lt;/strong&gt;&lt;/p&gt; &lt;table style=&quot;border-collapse: collapse; width:100%; border-collapse:collapse ;&quot;&gt;&lt;tr&gt;&lt;td style=&quot;max-width:25%; width:25%; min-width:25%;;vertical-align: top ; &quot;&gt;Date:&lt;/td&gt;&lt;td style=&quot;max-width:75%; width:75%; min-width:75%;;vertical-align: top ; &quot;&gt;Monday, November 9th&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style=&quot;vertical-align: top ; &quot;&gt;Time:&lt;/td&gt;&lt;td style=&quot;vertical-align: top ; &quot;&gt;8:30</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/LifeMD+to+Report+Third+Quarter+2026+Financial+Results+on+November+9/27210422.html</guid>
   <pubDate>Tue, 20 Oct 2026 16:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMDP</category>
   	  </item>
  <item>
   <title>LifeMD to Report Third Quarter 2026 Financial Results on November 9</title>
   <link>http://www.streetinsider.com/Globe+Newswire/LifeMD+to+Report+Third+Quarter+2026+Financial+Results+on+November+9/27210422.html</link>
   <description>
&lt;p align=&quot;justify&quot;&gt;NEW YORK, Oct.  20, 2026  (GLOBE NEWSWIRE) -- &lt;strong&gt;LifeMD, Inc. (Nasdaq: LFMD)&lt;/strong&gt;, a leading provider of virtual primary care and pharmacy services, announces that it will report financial results for the three and nine months ended September 30, 2026, before the open of the U.S. financial markets on November 9, 2026, and will host a conference call beginning at 8:30 a.m. Eastern time.&lt;/p&gt;  &lt;p&gt;&lt;strong&gt;Conference Call &amp;amp; Webcast Details&lt;/strong&gt;&lt;/p&gt; &lt;table style=&quot;border-collapse: collapse; width:100%; border-collapse:collapse ;&quot;&gt;&lt;tr&gt;&lt;td style=&quot;max-width:25%; width:25%; min-width:25%;;vertical-align: top ; &quot;&gt;Date:&lt;/td&gt;&lt;td style=&quot;max-width:75%; width:75%; min-width:75%;;vertical-align: top ; &quot;&gt;Monday, November 9th&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style=&quot;vertical-align: top ; &quot;&gt;Time:&lt;/td&gt;&lt;td style=&quot;vertical-align: top ; &quot;&gt;8:30</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/LifeMD+to+Report+Third+Quarter+2026+Financial+Results+on+November+9/27210422.html</guid>
   <pubDate>Tue, 20 Oct 2026 16:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMDP</category>
   	  </item>
  <item>
   <title>LifeMD to Report Third Quarter 2026 Financial Results on November 9</title>
   <link>http://www.streetinsider.com/Press+Releases/LifeMD+to+Report+Third+Quarter+2026+Financial+Results+on+November+9/27210422.html</link>
   <description>
&lt;p align=&quot;justify&quot;&gt;NEW YORK, Oct.  20, 2026  (GLOBE NEWSWIRE) -- &lt;strong&gt;LifeMD, Inc. (Nasdaq: LFMD)&lt;/strong&gt;, a leading provider of virtual primary care and pharmacy services, announces that it will report financial results for the three and nine months ended September 30, 2026, before the open of the U.S. financial markets on November 9, 2026, and will host a conference call beginning at 8:30 a.m. Eastern time.&lt;/p&gt;  &lt;p&gt;&lt;strong&gt;Conference Call &amp;amp; Webcast Details&lt;/strong&gt;&lt;/p&gt; &lt;table style=&quot;border-collapse: collapse; width:100%; border-collapse:collapse ;&quot;&gt;&lt;tr&gt;&lt;td style=&quot;max-width:25%; width:25%; min-width:25%;;vertical-align: top ; &quot;&gt;Date:&lt;/td&gt;&lt;td style=&quot;max-width:75%; width:75%; min-width:75%;;vertical-align: top ; &quot;&gt;Monday, November 9th&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style=&quot;vertical-align: top ; &quot;&gt;Time:&lt;/td&gt;&lt;td style=&quot;vertical-align: top ; &quot;&gt;8:30</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/LifeMD+to+Report+Third+Quarter+2026+Financial+Results+on+November+9/27210422.html</guid>
   <pubDate>Tue, 20 Oct 2026 16:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMDP</category>
   	  </item>
  <item>
   <title>LifeMD to Report Third Quarter 2026 Financial Results on November 9</title>
   <link>http://www.streetinsider.com/Globe+Newswire/LifeMD+to+Report+Third+Quarter+2026+Financial+Results+on+November+9/27210422.html</link>
   <description>
&lt;p align=&quot;justify&quot;&gt;NEW YORK, Oct.  20, 2026  (GLOBE NEWSWIRE) -- &lt;strong&gt;LifeMD, Inc. (Nasdaq: LFMD)&lt;/strong&gt;, a leading provider of virtual primary care and pharmacy services, announces that it will report financial results for the three and nine months ended September 30, 2026, before the open of the U.S. financial markets on November 9, 2026, and will host a conference call beginning at 8:30 a.m. Eastern time.&lt;/p&gt;  &lt;p&gt;&lt;strong&gt;Conference Call &amp;amp; Webcast Details&lt;/strong&gt;&lt;/p&gt; &lt;table style=&quot;border-collapse: collapse; width:100%; border-collapse:collapse ;&quot;&gt;&lt;tr&gt;&lt;td style=&quot;max-width:25%; width:25%; min-width:25%;;vertical-align: top ; &quot;&gt;Date:&lt;/td&gt;&lt;td style=&quot;max-width:75%; width:75%; min-width:75%;;vertical-align: top ; &quot;&gt;Monday, November 9th&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style=&quot;vertical-align: top ; &quot;&gt;Time:&lt;/td&gt;&lt;td style=&quot;vertical-align: top ; &quot;&gt;8:30</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/LifeMD+to+Report+Third+Quarter+2026+Financial+Results+on+November+9/27210422.html</guid>
   <pubDate>Tue, 20 Oct 2026 16:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMDP</category>
   	  </item>
  <item>
   <title>Form  S-8        LifeMD, Inc.                         </title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++LifeMD%2C+Inc.+++++++++++++++++++++++++/27108028.html</link>
   <description>si-local-file:///var/storage/secattach/20260925/27108028.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++LifeMD%2C+Inc.+++++++++++++++++++++++++/27108028.html</guid>
   <pubDate>Fri, 25 Sep 2026 16:51:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMDP</category>
   	  </item>
  <item>
   <title>Form  S-8        LifeMD, Inc.                         </title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++LifeMD%2C+Inc.+++++++++++++++++++++++++/27108028.html</link>
   <description>si-local-file:///var/storage/secattach/20260925/27108028.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++LifeMD%2C+Inc.+++++++++++++++++++++++++/27108028.html</guid>
   <pubDate>Fri, 25 Sep 2026 16:51:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMDP</category>
   	  </item>
  <item>
   <title>LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock</title>
   <link>http://www.streetinsider.com/Press+Releases/LifeMD+Declares+Quarterly+Dividend+on+Series+A+Cumulative+Perpetual+Preferred+Stock/27091732.html</link>
   <description>
&lt;p align=&quot;justify&quot;&gt;NEW YORK, Sept.  22, 2026  (GLOBE NEWSWIRE) -- &lt;a target=&quot;_blank&quot; href=&quot;https://www.globenewswire.com/Tracker?data=w_zNMTfL60LNDlrtsVAMYamXF-dH8hfCgV854GbNPMXtRlRDJffzDerV2MZfg3qQrDWiuUXDLEVWm-C3C-xDRg==&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;LifeMD, Inc.&lt;/a&gt; (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company’s 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share.&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;The preferred dividend will be paid on October 15, 2026, to holders of record at the close of business on October 2, 2026.&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;About LifeMD, Inc.&lt;/strong&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;LifeMD® is a leading virtual care company making</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/LifeMD+Declares+Quarterly+Dividend+on+Series+A+Cumulative+Perpetual+Preferred+Stock/27091732.html</guid>
   <pubDate>Tue, 22 Sep 2026 17:01:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMDP</category>
   	  </item>
  <item>
   <title>LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock</title>
   <link>http://www.streetinsider.com/Globe+Newswire/LifeMD+Declares+Quarterly+Dividend+on+Series+A+Cumulative+Perpetual+Preferred+Stock/27091732.html</link>
   <description>
&lt;p align=&quot;justify&quot;&gt;NEW YORK, Sept.  22, 2026  (GLOBE NEWSWIRE) -- &lt;a target=&quot;_blank&quot; href=&quot;https://www.globenewswire.com/Tracker?data=w_zNMTfL60LNDlrtsVAMYamXF-dH8hfCgV854GbNPMXtRlRDJffzDerV2MZfg3qQrDWiuUXDLEVWm-C3C-xDRg==&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;LifeMD, Inc.&lt;/a&gt; (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company’s 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share.&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;The preferred dividend will be paid on October 15, 2026, to holders of record at the close of business on October 2, 2026.&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;About LifeMD, Inc.&lt;/strong&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;LifeMD® is a leading virtual care company making</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/LifeMD+Declares+Quarterly+Dividend+on+Series+A+Cumulative+Perpetual+Preferred+Stock/27091732.html</guid>
   <pubDate>Tue, 22 Sep 2026 17:01:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMDP</category>
   	  </item>
  <item>
   <title>LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock</title>
   <link>http://www.streetinsider.com/Press+Releases/LifeMD+Declares+Quarterly+Dividend+on+Series+A+Cumulative+Perpetual+Preferred+Stock/27091732.html</link>
   <description>
&lt;p align=&quot;justify&quot;&gt;NEW YORK, Sept.  22, 2026  (GLOBE NEWSWIRE) -- &lt;a target=&quot;_blank&quot; href=&quot;https://www.globenewswire.com/Tracker?data=w_zNMTfL60LNDlrtsVAMYamXF-dH8hfCgV854GbNPMXtRlRDJffzDerV2MZfg3qQrDWiuUXDLEVWm-C3C-xDRg==&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;LifeMD, Inc.&lt;/a&gt; (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company’s 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share.&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;The preferred dividend will be paid on October 15, 2026, to holders of record at the close of business on October 2, 2026.&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;About LifeMD, Inc.&lt;/strong&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;LifeMD® is a leading virtual care company making</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/LifeMD+Declares+Quarterly+Dividend+on+Series+A+Cumulative+Perpetual+Preferred+Stock/27091732.html</guid>
   <pubDate>Tue, 22 Sep 2026 17:01:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMDP</category>
   	  </item>
  <item>
   <title>LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock</title>
   <link>http://www.streetinsider.com/Globe+Newswire/LifeMD+Declares+Quarterly+Dividend+on+Series+A+Cumulative+Perpetual+Preferred+Stock/27091732.html</link>
   <description>
&lt;p align=&quot;justify&quot;&gt;NEW YORK, Sept.  22, 2026  (GLOBE NEWSWIRE) -- &lt;a target=&quot;_blank&quot; href=&quot;https://www.globenewswire.com/Tracker?data=w_zNMTfL60LNDlrtsVAMYamXF-dH8hfCgV854GbNPMXtRlRDJffzDerV2MZfg3qQrDWiuUXDLEVWm-C3C-xDRg==&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;LifeMD, Inc.&lt;/a&gt; (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company’s 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share.&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;The preferred dividend will be paid on October 15, 2026, to holders of record at the close of business on October 2, 2026.&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;About LifeMD, Inc.&lt;/strong&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;LifeMD® is a leading virtual care company making</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/LifeMD+Declares+Quarterly+Dividend+on+Series+A+Cumulative+Perpetual+Preferred+Stock/27091732.html</guid>
   <pubDate>Tue, 22 Sep 2026 17:01:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMDP</category>
   	  </item>
  <item>
   <title>Form  8-K        LifeMD, Inc.              For: Sep 15</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++LifeMD%2C+Inc.++++++++++++++For%3A+Sep+15/27063037.html</link>
   <description>si-local-file:///var/storage/secattach/20260915/27063037.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++LifeMD%2C+Inc.++++++++++++++For%3A+Sep+15/27063037.html</guid>
   <pubDate>Tue, 15 Sep 2026 10:19:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMDP</category>
   	  </item>
  <item>
   <title>Form  8-K        LifeMD, Inc.              For: Sep 15</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++LifeMD%2C+Inc.++++++++++++++For%3A+Sep+15/27063037.html</link>
   <description>si-local-file:///var/storage/secattach/20260915/27063037.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++LifeMD%2C+Inc.++++++++++++++For%3A+Sep+15/27063037.html</guid>
   <pubDate>Tue, 15 Sep 2026 10:19:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMDP</category>
   	  </item>
  <item>
   <title>UPDATE - LifeMD Reports Second Quarter 2026 Results</title>
   <link>http://www.streetinsider.com/Press+Releases/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html</link>
   <description>
&lt;p&gt;UPDATE this press release has been updated to remove a duplicate table. &lt;/p&gt;  &lt;ul&gt;&lt;li&gt;Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.&lt;/li&gt;&lt;li&gt;Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.&lt;/li&gt;&lt;li&gt;Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html</guid>
   <pubDate>Wed, 05 Aug 2026 19:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.15159508</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.30035300</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMDP</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00649154</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.09946953</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20947283</category>
   	  </item>
  <item>
   <title>UPDATE - LifeMD Reports Second Quarter 2026 Results</title>
   <link>http://www.streetinsider.com/Globe+Newswire/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html</link>
   <description>
&lt;p&gt;UPDATE this press release has been updated to remove a duplicate table. &lt;/p&gt;  &lt;ul&gt;&lt;li&gt;Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.&lt;/li&gt;&lt;li&gt;Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.&lt;/li&gt;&lt;li&gt;Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html</guid>
   <pubDate>Wed, 05 Aug 2026 19:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.15159508</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.30035300</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMDP</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00649154</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.09946953</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20947283</category>
   	  </item>
  <item>
   <title>UPDATE - LifeMD Reports Second Quarter 2026 Results</title>
   <link>http://www.streetinsider.com/Press+Releases/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html</link>
   <description>
&lt;p&gt;UPDATE this press release has been updated to remove a duplicate table. &lt;/p&gt;  &lt;ul&gt;&lt;li&gt;Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.&lt;/li&gt;&lt;li&gt;Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.&lt;/li&gt;&lt;li&gt;Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html</guid>
   <pubDate>Wed, 05 Aug 2026 19:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.15159508</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.30035300</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMDP</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00649154</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.09946953</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20947283</category>
   	  </item>
  <item>
   <title>UPDATE - LifeMD Reports Second Quarter 2026 Results</title>
   <link>http://www.streetinsider.com/Globe+Newswire/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html</link>
   <description>
&lt;p&gt;UPDATE this press release has been updated to remove a duplicate table. &lt;/p&gt;  &lt;ul&gt;&lt;li&gt;Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.&lt;/li&gt;&lt;li&gt;Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.&lt;/li&gt;&lt;li&gt;Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html</guid>
   <pubDate>Wed, 05 Aug 2026 19:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.15159508</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.30035300</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMDP</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00649154</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.09946953</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20947283</category>
   	  </item>
  <item>
   <title>UPDATE - LifeMD Reports Second Quarter 2026 Results</title>
   <link>http://www.streetinsider.com/Press+Releases/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html</link>
   <description>
&lt;p&gt;UPDATE this press release has been updated to remove a duplicate table. &lt;/p&gt;  &lt;ul&gt;&lt;li&gt;Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.&lt;/li&gt;&lt;li&gt;Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.&lt;/li&gt;&lt;li&gt;Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html</guid>
   <pubDate>Wed, 05 Aug 2026 19:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.15159508</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.30035300</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMDP</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00649154</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.09946953</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20947283</category>
   	  </item>
  <item>
   <title>UPDATE - LifeMD Reports Second Quarter 2026 Results</title>
   <link>http://www.streetinsider.com/Globe+Newswire/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html</link>
   <description>
&lt;p&gt;UPDATE this press release has been updated to remove a duplicate table. &lt;/p&gt;  &lt;ul&gt;&lt;li&gt;Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.&lt;/li&gt;&lt;li&gt;Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.&lt;/li&gt;&lt;li&gt;Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html</guid>
   <pubDate>Wed, 05 Aug 2026 19:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.15159508</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.30035300</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMDP</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00649154</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.09946953</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20947283</category>
   	  </item>
  <item>
   <title>UPDATE - LifeMD Reports Second Quarter 2026 Results</title>
   <link>http://www.streetinsider.com/Press+Releases/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html</link>
   <description>
&lt;p&gt;UPDATE this press release has been updated to remove a duplicate table. &lt;/p&gt;  &lt;ul&gt;&lt;li&gt;Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.&lt;/li&gt;&lt;li&gt;Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.&lt;/li&gt;&lt;li&gt;Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html</guid>
   <pubDate>Wed, 05 Aug 2026 19:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.15159508</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.30035300</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMDP</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00649154</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.09946953</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20947283</category>
   	  </item>
  <item>
   <title>UPDATE - LifeMD Reports Second Quarter 2026 Results</title>
   <link>http://www.streetinsider.com/Globe+Newswire/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html</link>
   <description>
&lt;p&gt;UPDATE this press release has been updated to remove a duplicate table. &lt;/p&gt;  &lt;ul&gt;&lt;li&gt;Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.&lt;/li&gt;&lt;li&gt;Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.&lt;/li&gt;&lt;li&gt;Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html</guid>
   <pubDate>Wed, 05 Aug 2026 19:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.15159508</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.30035300</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMDP</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00649154</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.09946953</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20947283</category>
   	  </item>
  <item>
   <title>UPDATE - LifeMD Reports Second Quarter 2026 Results</title>
   <link>http://www.streetinsider.com/Press+Releases/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html</link>
   <description>
&lt;p&gt;UPDATE this press release has been updated to remove a duplicate table. &lt;/p&gt;  &lt;ul&gt;&lt;li&gt;Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.&lt;/li&gt;&lt;li&gt;Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.&lt;/li&gt;&lt;li&gt;Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html</guid>
   <pubDate>Wed, 05 Aug 2026 19:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.15159508</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.30035300</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMDP</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00649154</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.09946953</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20947283</category>
   	  </item>
  <item>
   <title>UPDATE - LifeMD Reports Second Quarter 2026 Results</title>
   <link>http://www.streetinsider.com/Globe+Newswire/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html</link>
   <description>
&lt;p&gt;UPDATE this press release has been updated to remove a duplicate table. &lt;/p&gt;  &lt;ul&gt;&lt;li&gt;Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.&lt;/li&gt;&lt;li&gt;Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.&lt;/li&gt;&lt;li&gt;Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html</guid>
   <pubDate>Wed, 05 Aug 2026 19:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.15159508</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.30035300</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMDP</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00649154</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.09946953</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20947283</category>
   	  </item>
  <item>
   <title>UPDATE - LifeMD Reports Second Quarter 2026 Results</title>
   <link>http://www.streetinsider.com/Press+Releases/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html</link>
   <description>
&lt;p&gt;UPDATE this press release has been updated to remove a duplicate table. &lt;/p&gt;  &lt;ul&gt;&lt;li&gt;Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.&lt;/li&gt;&lt;li&gt;Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.&lt;/li&gt;&lt;li&gt;Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html</guid>
   <pubDate>Wed, 05 Aug 2026 19:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.15159508</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.30035300</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMDP</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00649154</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.09946953</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20947283</category>
   	  </item>
  <item>
   <title>UPDATE - LifeMD Reports Second Quarter 2026 Results</title>
   <link>http://www.streetinsider.com/Globe+Newswire/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html</link>
   <description>
&lt;p&gt;UPDATE this press release has been updated to remove a duplicate table. &lt;/p&gt;  &lt;ul&gt;&lt;li&gt;Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.&lt;/li&gt;&lt;li&gt;Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.&lt;/li&gt;&lt;li&gt;Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html</guid>
   <pubDate>Wed, 05 Aug 2026 19:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.15159508</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.30035300</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMDP</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00649154</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.09946953</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20947283</category>
   	  </item>
  <item>
   <title>UPDATE - LifeMD Reports Second Quarter 2026 Results</title>
   <link>http://www.streetinsider.com/Press+Releases/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html</link>
   <description>
&lt;p&gt;UPDATE this press release has been updated to remove a duplicate table. &lt;/p&gt;  &lt;ul&gt;&lt;li&gt;Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.&lt;/li&gt;&lt;li&gt;Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.&lt;/li&gt;&lt;li&gt;Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html</guid>
   <pubDate>Wed, 05 Aug 2026 19:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.15159508</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.30035300</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">LFMDP</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00649154</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.09946953</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20947283</category>
   	  </item>
 </channel>
</rss>
